Anne-Marie D.
- Country
- The Netherlands
- Department
- Internal medicine/Oncology
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Evaluation of Image-Guided De-Escalation of Neoadjuvant Chemotherapy with Trastuzumab, Pertuzumab, and Drug Combination in HER2-Positive Breast Cancer
- Evaluation of CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib in HR+/HER2- Metastatic Breast Cancer: A Randomized Clinical Trial
Data & Insights
Has run more than one trial at 81 of 332 partner sites.
Specializations
Breast Cancer Treatment
This investigator specializes in the treatment of hormone receptor-positive breast cancer, with particular focus on developing therapeutic strategies for both early-stage and advanced disease states.
- HER2-positive breast cancer management
- Endocrine therapy optimization
- Advanced treatment protocols
The research encompasses innovative approaches in neoadjuvant chemotherapy and targeted therapies.
Endocrine Therapy Innovation
The investigator focuses on advancing endocrine-based therapeutic approaches, particularly in the context of breast cancer treatment and symptom management.
- CDK4/6 inhibition strategies
- Extended adjuvant therapy
- Treatment sequencing optimization
Research interests include the development of novel therapeutic combinations for hormone-dependent cancers.
Symptom Management
The investigator studies interventions for managing treatment-related symptoms, with particular emphasis on vasomotor symptoms in cancer patients.
- Hot flash management
- Quality of life improvement
- Supportive care strategies
Research focuses on developing solutions for treatment-induced side effects in cancer therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.